Self‐efficacy (for physical activity) (SEPA, score · adults
1 finding from 1 review
Leisure time physical activity (LTPA)(kcal/week) · adults
1 finding from 1 review
Total activity time (TAA) (min/week) · adults
1 finding from 1 review
Intervention not reported
Adherence to treatment (number of participants undertaking physical activity) · people with CF
It is very uncertain whether the intervention changes adherence to treatment (number of participants undertaking physical… (very low certainty).
1 finding from 1 review
Disease activity · people with inflammatory bowel disease
1 finding from 1 review
Disease activity · people with inflammatory bowel disease
1 finding from 1 review
Disease activity · people with inflammatory bowel disease
1 finding from 1 review
Intervention not reported
Functioningi ‐ overall analysis Using different functioning scales: FSQ (range 0 to 36), BI (range 0 to 100), AM‐PAC daily activity (range 9 to 101), COPM (range 0 to 20), LEFS (range 0 to 80), NEADL (range 0 to 66). A higher score indicates bette... · adults following hip fracture surgery
The intervention leads to higher functioningi ‐ overall analysis Using different functioning scales:… (high certainty).
1 finding from 1 review
Fatigue –reduced activity Subscale from CIS · people with a primary brain tumour
1 finding from 1 review
Return to activity · adults with fractures of the patella
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
Oral ferric maltol showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV ferric carboxymaltose (low certainty).
1 finding from 1 review
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with multiple sclerosis
It is very uncertain whether antioxidant changes MRI activity(assessed as number of participants with… compared with placebo (very low certainty).
1 finding from 1 review
MRI activity ‐ not measured · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
MRI activity(assessed by new gadolinium‐enhancing lesions) · people with multiple sclerosis
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review